@article{e596b4d5faa34da8996d1dea92f79158,
title = "SLC1A2 rs3794087 does not associate with essential tremor",
abstract = "A recent genome-wide association study of patients with essential tremor (ET) from Germany has nominated SLC1A2 rs3794087 as a novel risk factor for disease. This association was independently replicated in the Chinese population, albeit with an opposite direction of effect. To further define the role of SLC1A2 in ET, we genotyped rs3794087 in a North American series consisting of 1347 patients with ET and controls. Statistical analysis did not identify significant differences in genotype or allele frequencies between healthy controls and patients with ET (p > 0.36). These findings therefore do not support a role for SLC1A2 rs3794087 in susceptibility to ET in the North American population. Further studies in ethnically distinct populations of patients with ET are necessary to understand whether genetic variability in SLC1A2 affects disease risk for ET.",
keywords = "Association, Essential tremor, SLC1A2",
author = "Ross, {Jay P.} and Sruti Rayaprolu and Bernales, {Cecily Q.} and Soto-Ortolaza, {Alexandra I.} and {van Gerpen}, Jay and Uitti, {Ryan J.} and Wszolek, {Zbigniew K.} and Alex Rajput and Rajput, {Ali H.} and Rajput, {Michele L.} and Ross, {Owen A.} and Carles Vilari{\~n}o-G{\"u}ell",
note = "Funding Information: This work was supported in part by a Morris K. Udall Parkinson's Disease Research Center of Excellence (National Institute of Neurological Disorders and Stoke [NINDS] P50 #NS072187 ), NINDS R01 NS078086 , the Mayo Clinic Research Program (O.A.R.), The Canada Research Chair program (C.V.-G.), Regina Curling Classic for Parkinson Research , Greystone Golf Classic for Parkinson's and the Royal University Hospital Foundation (A.R., A.H.R.). A.R. has received personal compensation (honoraria) from Merz (including travel funding), Allergan (including travel funding), Teva, Novartis, Taro Pharmaceuticals, and the Canadian Psychiatric Research Foundation. He has received research support from Regina Curling Classic, Greystone Classic for Parkinson's, and Alex Rajput Endowment for Parkinson's Disease and Movement Disorders. Clinical trials have been supported by Merck-Serono SA-Geneva (EMR 701165-024 ), Teva (TVP- 1012/501 ), National Institutes of Health (NIH)/NINDS ( U01 NS050324-01A1 ). Has provided expert testimony on behalf of the Canadian Medical Protection Association (CMPA). A.H.R. receives research support from the Saskatchewan Parkinson's Disease Foundation , Curling Classic , and PrintWest Golf Classic , and has received a travel grant from Teva . Z.K.W. is funded by NIH NS072187 and is the Editor in Chief of Parkinsonism and Related Disorders. O.A.R. is a member of the editorial board of PLoS One and Parkinsonism and Related Disorders, and is funded by NIH grants NS078086 and NS072187 . J.P.R., S.R., C.Q.B., A.I.S.-O., M.L.R., J.vG., R.J.U., and C.V.-G. report nothing to disclose. ",
year = "2014",
month = apr,
doi = "10.1016/j.neurobiolaging.2013.09.022",
language = "English (US)",
volume = "35",
pages = "935.e9--935.e10",
journal = "Neurobiology of aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "4",
}